CompoAtlas

TRAZESIL Herbal Cough Lozenges Orange Flavor

Idioma del texto original no especificado por la fuente.

TRAZESIL Herbal Cough Lozenges Orange Flavor : Producto registrado en Malasia. Este registro no constituye una autorización de venta en Francia ni en la Unión Europea. No demuestra la seguridad ni la eficacia del producto.

NPRA, registro malasio de productos farmacéuticos, consultado el 27 de octubre de 2026.

Ministerio de Salud de Malasia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Texto original en inglés.

La categoría del registro extranjero no determina la categoría reglamentaria del producto en Francia.

Referencias francesas y europeas para los ingredientes reconocidos

No se evalúan los ingredientes no identificados. La ausencia de señales no demuestra la conformidad del producto.

Composición publicada

Ingrediente publicadoTexto y cantidad publicadosNutriente o sustancia identificados
Mentha piperitaMentha piperita[2 mg,2.5 gm]No identificado
Adhatoda vasicaAdhatoda vasica[5 mg,2.5 gm]No identificado
Piper longumPiper longum[25 mg,2.5 gm]No identificado
Piper nigrumPiper nigrum[20 mg,2.5 gm]No identificado
Zingiber officinaleZingiber officinale[12 mg,2.5 gm]No identificado
Glycyrrhiza glabraGlycyrrhiza glabra[10 mg,2.5 gm]No identificado
Curcuma longaCurcuma longa[15 mg,2.5 gm]No identificado
Acacia catechuAcacia catechu[17 mg,2.5 gm]No identificado
Foeniculum vulgareFoeniculum vulgare[18 mg,2.5 gm]No identificado
Ocimum sanctumOcimum sanctum[5 mg,2.5 gm]No identificado
Terminalia chebulaTerminalia chebula[5 mg,2.5 gm]No identificado
Terminalia belericaTerminalia belerica[5 mg,2.5 gm]No identificado
Alpinia galangaAlpinia galanga[20 mg,2.5 gm]No identificado
Abrus precatoriusAbrus precatorius[20 mg,2.5 gm]No identificado

Los datos importados no proporcionan una posología diaria utilizable. No se estima ninguna dosis diaria ni se realiza ninguna comparación con los límites de dosis. Una cantidad publicada puede referirse a un preparado o a una unidad no especificada. Los nombres chinos se conservan sin traducción.

Ficha del producto

Número de registro
MAL20056034TC
Tipo
Producto natural
Estado publicado
PRODUCT APPROVED
Titular
PHARMAVENTURES CORPORATION SDN. BHD.
Fabricante
M/S Prince Supplico
Importador
BioCare Pharmaceutical (M) Sdn. Bhd.
Inicio del periodo de registro
2025-05-22
Fin de validez publicado
2030-05-22

Datos originales del registro

Consultar los campos publicados y sus variantes
Ingredientes activos
Mentha piperita[2 mg,2.5 gm],Adhatoda vasica[5 mg,2.5 gm],Piper longum[25 mg,2.5 gm],Piper nigrum[20 mg,2.5 gm],Zingiber officinale[12 mg,2.5 gm],Glycyrrhiza glabra[10 mg,2.5 gm],Curcuma longa[15 mg,2.5 gm],Acacia catechu[17 mg,2.5 gm],Foeniculum vulgare[18 mg,2.5 gm],Ocimum sanctum[5 mg,2.5 gm],Terminalia chebula[5 mg,2.5 gm],Terminalia belerica[5 mg,2.5 gm],Alpinia galanga[20 mg,2.5 gm],Abrus precatorius[20 mg,2.5 gm]
Fin de validez
2030-05-22
Fecha de registro
2025-05-22
Descripción publicada
NATURAL PRODUCT
Titular
PHARMAVENTURES CORPORATION SDN. BHD.
Importador
BioCare Pharmaceutical (M) Sdn. Bhd.
Productor
M/S Prince Supplico
Nombre publicado
TRAZESIL Herbal Cough Lozenges Orange Flavor
Referencia publicada
201912053101T
Número de registro
MAL20056034TC
Estado publicado
PRODUCT APPROVED

Fuente oficial

Consultar el registro oficial, número MAL20056034TC

Ministerio de Salud de Malasia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Mentha piperita
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    PEPPERMINT - MENTHA X PIPERITA

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).

    Fuentes citadas por Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Condición de aplicación: Essential oil.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Reacciones adversas conocidas

    Condición de aplicación: Essential oil.

    When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Fuentes citadas por Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).

    Fuentes citadas por Health Canada (2)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografía de Health Canada del 27 de febrero de 2026

  • Zingiber officinale
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GINGER - ZINGIBER OFFICINALE

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 19 de diciembre de 2025

  • Glycyrrhiza glabra
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    DEGLYCYRRHIZINATED LICORICE Buccal

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 31 de octubre de 2025

    Deglycyrrhizinated Licorice Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 31 de enero de 2025

    LICORICE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    Fuentes citadas por Health Canada (1)
    • Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.

    Condición de aplicación: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    Fuentes citadas por Health Canada (1)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf

    Condición de aplicación: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you are pregnant (EMA 2012).

    Fuentes citadas por Health Canada (2)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    Fuentes citadas por Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    Fuentes citadas por Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Monografía de Health Canada del 29 de noviembre de 2024

  • Curcuma longa
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    TURMERIC - CURCUMA LONGA - Oral

    Vía de administración: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Fuentes citadas por Health Canada (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Fuentes citadas por Health Canada (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Fuentes citadas por Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Fuentes citadas por Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Condición de aplicación: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 26 de septiembre de 2025

    Turmeric -CURCUMA LONGA - Topical

    Precauciones y advertencias

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Contraindicaciones

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografía de Health Canada del 28 de febrero de 2025

  • Foeniculum vulgare
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    BITTER FENNEL- FOENICULUM VULGARE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Fuentes citadas por Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condición de aplicación: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Fuentes citadas por Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Fuentes citadas por Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Monografía de Health Canada del 29 de noviembre de 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Fuentes citadas por Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Fuentes citadas por Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Monografía de Health Canada del 29 de noviembre de 2024

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Se desconoce la fecha de la prueba de esta lista de ingredientes.

¿Ha cambiado el producto? Fotografíe el envase.

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Intro para analizar, Mayús+Intro para una nueva línea